X4 Pharmaceuticals plans 50% job cut, $13M savings

X4 Pharmaceuticals is undertaking a major restructuring to focus resources on completing its 4WARD Phase 3 trial in chronic neutropenia.

Accepted by SEC EDGAR 09/17/2025 - 07:03 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

X4 Pharmaceuticals is undertaking a major restructuring to focus resources on completing its 4WARD Phase 3 trial in chronic neutropenia. The plan includes reducing its workforce by approximately 50%, which is expected to generate about $13 million in annualized cost savings and result in an estimated $3.3 million of severance and related cash charges.

As part of the actions, the company terminated its Chief Operating Officer, Chief Commercial Officer, and Chief Legal & Compliance Officer effective September 15, 2025, and its Chief Medical Officer resigned effective September 16, 2025. The Board appointed John Volpone as Chief Operating Officer, and he will also continue serving as President. X4 notes that actual restructuring costs and benefits may differ from current estimates.

Positive

• None.

Negative

• Major workforce reduction and leadership turnover: X4 is cutting its workforce by approximately 50% and simultaneously losing or removing several key executives, including its Chief Operating Officer and Chief Medical Officer, which introduces operational and execution risk even as it targets $13 million in annualized cost savings.

Insights

Biotech equity analyst

Large restructuring with 50% job cuts trades near-term disruption for cost savings and a tighter focus on the 4WARD Phase 3 trial.

X4 Pharmaceuticals is cutting roughly half of its workforce to concentrate on the 4WARD Phase 3 study in moderate and severe chronic neutropenia. Management expects about $13 million in annualized cost savings, offset initially by around $3.3 million in severance and related cash charges.

The move also reshapes senior leadership. The Chief Operating Officer, Chief Commercial Officer, and Chief Legal & Compliance Officer were terminated effective September 15, 2025, and the Chief Medical Officer resigned effective September 16, 2025. John Volpone has been appointed Chief Operating Officer while continuing as President, consolidating operational control during this restructuring.

X4 cautions that actual restructuring costs and benefits may differ from estimates and that the restructuring could negatively affect business operations or fail to deliver intended benefits. Execution of the 4WARD Phase 3 trial under a leaner organization becomes a key operational test, with further details likely in future periodic filings.

8-K Event Classification

4 items: 2.05, 5.02, 7.01, 9.01

4 items

Item 2.05 Costs Associated with Exit or Disposal Activities Financial

The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What restructuring did X4 Pharmaceuticals (XFOR) announce?

X4 Pharmaceuticals announced a strategic restructuring to sharpen its operational focus on completing the 4WARD Phase 3 trial in chronic neutropenia. The plan centers on a workforce reduction and leadership changes, aiming to align spending with its long-term development strategy.

How many jobs will X4 Pharmaceuticals (XFOR) cut and why?

X4 Pharmaceuticals plans to reduce its workforce by approximately 50% as part of a strategic restructuring. The goal is to concentrate resources on successfully completing the 4WARD Phase 3 chronic neutropenia trial while lowering operating expenses through significant annualized cost savings.

What cost savings and charges does X4 Pharmaceuticals (XFOR) expect from the restructuring?

X4 Pharmaceuticals expects approximately $13 million in annualized cost savings from the restructuring. It estimates about $3.3 million in cash charges for severance and other employee termination-related costs, and notes that actual costs and benefits may differ from these current estimates.

Which X4 Pharmaceuticals (XFOR) executives are leaving the company?

The Board terminated Dr. Mary DiBiase (Chief Operating Officer), Mark Baldry (Chief Commercial Officer), and Natasha Thoren (Chief Legal & Compliance Officer) effective September 15, 2025. Chief Medical Officer Dr. Christophe Arbet-Engels resigned effective September 16, 2025, as part of changes linked to the restructuring.

Who is the new Chief Operating Officer at X4 Pharmaceuticals (XFOR)?

On September 16, 2025, X4 Pharmaceuticals’ Board appointed John Volpone as Chief Operating Officer, effective immediately. He will continue to serve as President, consolidating leadership roles as the company executes its restructuring and focuses resources on the 4WARD Phase 3 chronic neutropenia trial.

What risks did X4 Pharmaceuticals (XFOR) highlight regarding the restructuring?

X4 Pharmaceuticals warned that restructuring costs may be greater than anticipated and the actions could negatively impact business operations. The company also notes the restructuring may not generate intended benefits as expected, alongside broader risks described in its recent Form 10-K and Form 10-Q filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001501697FALSE00015016972025-09-152025-09-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2025

X4 PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38295

27-3181608

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

61 North Beacon Street,			4th Floor
Boston,			Massachusetts						02134
(Address of principal executive offices)									(Zip Code)

Registrant’s telephone number, including area code is (857) 529-8300

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

XFOR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.05 Costs Associated with Exit or Disposal Activities.

On September 17, 2025, X4 Pharmaceuticals, Inc. (the “Company” or “X4”) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long‑term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia.

As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs.

The estimate of costs that the Company expects to incur related to the workforce reduction as well as the decrease in spending, and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the actions described above.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Operating Officer, Chief Commercial Officer, Chief Legal & Compliance Officer and Chief Medical Officer

In connection with the workforce reduction discussed above, on September 15, 2025, the Board of Directors (the “Board”) determined to terminate the employment of Dr. Mary DiBiase, the Company’s Chief Operating Officer, Mark Baldry, the Company’s Chief Commercial Officer, and Natasha Thoren, the Company’s Chief Legal & Compliance Officer, in each case effective as of September 15, 2025.

On September 16, 2025, Dr. Christophe Arbet-Engels informed the Company of his resignation as the Company’s Chief Medical Officer, effective as of September 16, 2025.

Appointment of Chief Operating Officer

On September 16, 2025, the Board appointed John Volpone as Chief Operating Officer of the Company, effective immediately. Mr. Volpone will continue to serve in his role as President of the Company.

Additional information with respect to Mr. Volpone and his appointment as an officer can be found under the heading “Appointment of President” in Item 5.02 of the Company’s Current Report on Form 8-K, filed on August 12, 2025 with the U.S. Securities and Exchange Commission (the “SEC”), and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On September 17, 2025, the Company issued a press release titled “X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation,” a copy of which is attached hereto as Exhibit 99.1.

The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements regarding the workforce reduction, including estimated costs, timing and expected benefits. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to the workforce reduction, such as the restructuring costs may be greater than anticipated, the restructuring may negatively impact the Company’s business operations, the restructuring may not generate the intended benefits to the extent or as quickly as anticipated, and other risks and uncertainties described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are on file with the SEC, and risks described in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Item 9.01						Financial Statements and Exhibits.
Exhibit No.						Description
99.1						Press Release, dated September 17, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

X4 PHARMACEUTICALS, INC.

Date: September 17, 2025

By:

/s/ David H. Kirske

Name:

David H. Kirske

Title:

Chief Financial Officer